Finvest
AHR Healthcare REITs · REIT · Senior housing · Healthcare real estate · Thesis updated July 12, 2026

Strong operator, demanding stock price

01 Running thesis

Growth is real, price is the question

AHR is executing well. In Q1 2026, total portfolio same-store NOI grew 12.1%. Same-store NOI means income from properties owned in both periods, so it helps show organic growth. Management also raised full-year 2026 same-store NOI guidance to 9% to 12%.

The bull case is simple. Senior housing demand is strong, AHR owns a scaled operator in Trilogy, and the balance sheet has improved. Leverage was 3.0x net debt to EBITDA in Q1 2026, down from 3.4x at year-end 2025. That gives the company more room to buy assets, fund growth, and handle higher rates.

The bear case is not that the business is broken. It is that high growth is hard to keep as the company gets larger. AHR also has more than $650 million of awarded acquisitions not yet closed, which means the team must buy well, integrate well, and avoid overpaying in a competitive market.

The current view is positive on operating quality but cautious on the stock price. If AHR keeps beating guidance, proves the new deals earn attractive returns, and expands margins in SHOP, the story can keep working. If growth slows while the market still prices AHR like a fast grower, the stock can disappoint.

May 2026The Q1 2026 Form 10-Q confirmed the operating trends already reported on the earnings call. AHR also said there were no material changes to its risk factors.
May 2026Q1 2026 was a beat-and-raise quarter. Total portfolio same-store NOI grew 12.1%, leverage fell to 3.0x net debt to EBITDA, and the awarded acquisition pipeline grew to more than $650 million.
Feb 2026AHR ended 2025 with 14.2% full-year total same-store NOI growth and 22% NFFO per share growth. Initial 2026 guidance called for another year of double-digit NFFO per share growth.
Nov 2025Q3 2025 showed faster growth and lower leverage. AHR reported 16.4% total same-store NOI growth and said year-to-date acquisitions had topped $575 million.
Aug 2025AHR raised 2025 NFFO and NOI guidance after strong first-half execution. Net debt to EBITDA fell to 3.7x, and the managed portfolio grew to about 75% of total NOI.
Feb 2025The Q4 2024 transcript could not be processed because of a data retrieval issue. The thesis stayed unchanged pending a clean source.
Nov 2024AHR completed the buyout of the remaining Trilogy minority stake. The deal increased control over its main growth engine and supported a stronger operating platform.
Aug 2024The initial thesis was built around AHR's fast-growing managed senior housing portfolio. Q2 2024 total same-store NOI grew 15.7%, and the planned Trilogy buyout became a key catalyst.
02 Business model

Own the beds, share the upside

AHR makes money in two main ways. In its managed senior housing assets, it earns resident fees and services revenue, then pays the operating costs of running the facilities. That gives AHR more upside when occupancy, prices, and margins improve, but it also means AHR feels labor cost and care cost pressure directly.

The second model is more like a landlord. AHR leases outpatient medical and triple-net properties to healthcare tenants. Triple-net means the tenant pays many property costs, such as taxes, insurance, and maintenance. This income tends to be steadier, but it grows slower.

Trilogy is the key difference. AHR fully owns Trilogy Health Services and uses its tools and know-how across more of the managed portfolio. That includes centralized revenue management, development skills, and operating playbooks that may help other senior housing partners lift occupancy and margins.

The model breaks if managed properties stop improving. AHR must keep filling beds, raise rates without losing residents, control labor costs, and make sure new acquisitions fit the platform. The leased book helps, but it is not large enough to carry the whole growth story by itself.

03 Product portfolio

Four ways AHR earns rent and fees

Growth engine

Integrated Senior Health Campuses

These are Trilogy-operated campuses with skilled nursing, assisted living, and independent living. Q1 2026 same-store NOI growth was 14.5%, making this the largest and most important profit driver.

Growth engine

Seniors Housing Operating Portfolio

SHOP properties are run with regional operators, while AHR takes part in the operating results. Q1 2026 same-store NOI growth was 19.7%, helped by occupancy gains and margin expansion.

Steady

Triple-Net Leased Properties

These properties are leased to healthcare operators under long-term leases. Management guided to 2% to 3% same-store NOI growth for 2026, so this is a stable but slower part of the business.

Steady

Outpatient Medical

This includes medical office buildings and other outpatient facilities. Management guided to 0% to 2% same-store NOI growth for 2026, so it adds stability more than speed.

04 Business segments

NOI still leans senior housing

Integrated Senior Health Campuses57%growing fast
Seniors Housing Operating Portfolio21%growing fast
Outpatient Medical15%flat
Triple-Net Leased Properties7%modest

Segment shares use Q1 2026 NOI from the Form 10-Q, calculated as segment revenue minus segment property or rental expenses. The managed segments, ISHC and SHOP, produced about 78% of Q1 2026 NOI, so AHR is highly tied to senior housing operations.

05 Risk factors

What could go wrong

Senior housing growth normalizes

High impact · Medium odds

AHR has posted several quarters of double-digit same-store NOI growth. That pace is hard to keep as occupancy moves higher and the base gets larger. If 2027 growth drops faster than investors expect, the stock could re-rate lower.

We watchWatch 2026 same-store NOI guidance, then 2027 guidance for Trilogy and SHOP.

Acquisition pipeline slips or under earns

High impact · Medium odds

AHR has more than $650 million of awarded acquisitions still to close. The pipeline can add growth, but it also brings integration risk. A more crowded market could push cap rates lower and reduce future returns.

We watchWatch deal closings, stabilized yield commentary, cap rates, and first-year NOI from acquired assets.

Labor and operating costs squeeze margins

Medium impact · Medium odds

Managed senior housing gives AHR upside, but it also exposes the company to wages, supplies, energy, and care staffing costs. The 10-Q says inflation has raised labor, services, energy, and supply costs. If rate increases do not offset those costs, NOI growth can slow.

We watchWatch ISHC and SHOP operating expense ratios and comments on staffing costs.

Occupancy and pricing hit a ceiling

Medium impact · Medium odds

AHR's combined ISHC and SHOP occupancy was 89.8% as of March 31, 2026. As occupancy moves toward the low 90s, the company may need more rate growth and less occupancy growth to keep NOI rising. Raising prices too fast could hurt move-ins or resident retention.

We watchWatch resident occupancy, RevPOR, and management's comments on the balance between rate and volume.

Leadership uncertainty lasts longer

Medium impact · Low odds

The 10-Q says CEO Danny Prosky is taking a medical leave from his executive role, while Jeffrey Hanson is serving as Chairman, Interim CEO, and President. The operating story remains intact, but a long unclear timeline can weigh on investor confidence. This matters more while AHR is closing a large acquisition pipeline.

We watchWatch company updates on the CEO's return timeline and any changes to acquisition or operating plans.
06 Quick answers

In one breath

What does American Healthcare REIT do?

AHR owns and operates healthcare real estate. Its main focus is senior housing and skilled nursing, with smaller exposure to outpatient medical buildings and triple-net leased healthcare properties.

Why is Trilogy important to AHR?

Trilogy operates AHR's integrated senior health campuses and is fully owned by AHR. The company is also using Trilogy's revenue and operating tools across other senior housing partners to try to lift margins and growth.

What is the main risk for AHR stock?

The main risk is that growth slows while the stock still prices in strong execution. Investors should watch same-store NOI growth, the over $650 million acquisition pipeline, and whether new deals add value after integration.